5-fluorouracil + cyclophosphamide + epirubicin + medroxyprogesterone acetate

This is a combination regimen consisting of four agents: - **5-fluorouracil** (5-FU): an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. - **Cyclophosphamide**: an alkylating agent that crosslinks DNA strands, leading to cell death. - **Epirubicin**: an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, causing DNA damage and apoptosis. - **Medroxyprogesterone acetate**: a synthetic progestin with hormonal activity used for its anti-tumor effects in hormone-responsive cancers. This combination has been studied primarily in advanced breast cancer and endometrial cancer. The rationale is to combine cytotoxic chemotherapy (CEF/FEC) with hormonal therapy (medroxyprogesterone acetate) to enhance anti-tumor efficacy. Clinical reports indicate use in patients with metastatic or recurrent disease, including those resistant to standard chemotherapy[1][2][3][4].

Other names

5-FU + cyclophosphamide + epirubicin + medroxyprogesterone acetateCEF plus medroxyprogesterone acetateFEC plus medroxyprogesterone acetate